Google DeepMind spinoff Isomorphic Labs plans to begin testing its first AI-designed drugs this year, aiming for clinical trials by year-end. The potential of AI in drug discovery could lead to faster and cheaper development of new therapies. With over 460 AI startups in drug discovery, partnerships with major pharmaceutical companies like Eli Lilly and Novartis are crucial for translating AI advancements into real treatments, despite ongoing challenges in clinical testing and approvals.